The Cost of Waiting:
The Economic Burden of a Delayed Spondyloarthritis Diagnosis in Canada

A delayed diagnosis of spondyloarthritis (SpA) carries a profound economic and personal cost in Canada, as highlighted in the 2025 CSA Burden of Illness Report. With more than 500,000 Canadians living with SpA and an average 13-year delay before receiving proper care, the impact extends far beyond health—driving significant losses in productivity, escalating healthcare use, and increasing travel-related costs. The findings show that delayed diagnosis contributes to a staggering $2.01 billion in annual costs for axial SpA and $1.25 billion for psoriatic arthritis, underscoring the urgent need for earlier detection, coordinated care, and national action. This report reveals not just the financial burden, but the human toll of years spent searching for answers, emphasizing why reducing the delay to diagnosis must be a Canadian healthcare priority.

Spondyloarthritis (SpA) is a group of inflammatory diseases including:
Axial SpA (axSpA), Psoriatic Arthritis (PsA), Enteropathic Arthritis, and Reactive Arthritis.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.